Israel Acquisitions Equties Warrants Exp 12 Dec 2027 Financials
This page shows Israel Acquisitions Equties Warrants Exp 12 Dec 2027 (ISRLW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Israel Acquisitions Equties Warrants Exp 12 Dec 2027's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Israel Acquisitions Equties Warrants Exp 12 Dec 2027's current ratio of 1.24 is below the typical benchmark, resulting in a score of 20/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Israel Acquisitions Equties Warrants Exp 12 Dec 2027 passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Israel Acquisitions Equties Warrants Exp 12 Dec 2027 generates $0.51 in operating cash flow (-$258K OCF vs -$510K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Israel Acquisitions Equties Warrants Exp 12 Dec 2027 reported -$510K in net income in fiscal year 2025. This represents a decrease of 118.1% from the prior year.
Cash & Balance Sheet
Israel Acquisitions Equties Warrants Exp 12 Dec 2027 held $7K in cash against $0 in long-term debt as of fiscal year 2025.
Margins & Returns
Capital Allocation
ISRLW Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | N/A | -$281K+19.5% | -$349K-24.1% | -$281K | N/A | -$234K+20.2% | -$294K+53.5% | -$632K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$180K+24.2% | -$238K-457.3% | $67K | N/A | $811K+9.7% | $739K+28.3% | $576K |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ISRLW Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $10.0M+0.7% | $9.9M+2.4% | $9.7M+1.9% | $9.5M-88.5% | $82.6M+1.3% | $81.6M+1.4% | $80.5M+1.1% | $79.6M |
| Current Assets | $10.0M+0.7% | $9.9M+2.4% | $9.7M+1.9% | $9.5M-88.5% | $82.6M+1.3% | $81.6M+1.4% | $80.5M+1.1% | $79.6M |
| Cash & Equivalents | $7K-89.1% | $64K+11.4% | $57K+110.6% | $27K+27.9% | $21K-20.4% | $27K-60.1% | $67K-79.0% | $318K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $18.0M+1.0% | $17.8M+3.4% | $17.2M+3.6% | $16.6M-81.5% | $89.5M+1.7% | $88.0M+1.7% | $86.5M+1.5% | $85.2M |
| Current Liabilities | $8.0M-0.1% | $8.0M+5.4% | $7.6M+5.9% | $7.2M+4.7% | $6.9M+5.7% | $6.5M+4.9% | $6.2M+2.1% | $6.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$8.0M-1.2% | -$7.9M-4.8% | -$7.5M-5.9% | -$7.1M-3.7% | -$6.9M-6.2% | -$6.5M-6.3% | -$6.1M-7.9% | -$5.6M |
| Retained Earnings | -$8.1M-3.1% | -$7.9M-4.8% | -$7.5M-5.9% | -$7.1M-3.7% | -$6.9M-6.2% | -$6.5M-6.3% | -$6.1M-7.9% | -$5.6M |
ISRLW Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $38K+136.5% | -$103K-75.8% | -$59K+56.3% | -$134K-115.5% | $865K+1.1% | $855K+9.7% | $780K-8.1% | $849K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$178K+3.2% | -$184K-1.1% | -$182K | N/A | -$1.1M+8.4% | -$1.2M-1.2% | -$1.2M-101.6% | $74.6M |
| Financing Cash Flow | $84K-71.5% | $294K+8.5% | $271K | N/A | $225K-25.0% | $300K+100.0% | $150K+100.2% | -$75.8M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $0 | $0 | $0 | N/A | $0 | $0 | $0-100.0% | $75.9M |
ISRLW Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | -1.8%+0.6pp | -2.5%-3.2pp | 0.7% | N/A | 1.0%+0.1pp | 0.9%+0.2pp | 0.7% |
| Current Ratio | 1.24+0.0 | 1.23-0.0 | 1.27-0.0 | 1.32-10.7 | 12.01-0.5 | 12.53-0.4 | 12.96-0.1 | 13.09 |
| Debt-to-Equity | -2.250.0 | -2.25+0.0 | -2.28+0.0 | -2.33+10.7 | -13.06+0.6 | -13.64+0.6 | -14.25+0.9 | -15.14 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$8.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Frequently Asked Questions
Is Israel Acquisitions Equties Warrants Exp 12 Dec 2027 profitable?
No, Israel Acquisitions Equties Warrants Exp 12 Dec 2027 (ISRLW) reported a net income of -$510K in fiscal year 2025.
What is Israel Acquisitions Equties Warrants Exp 12 Dec 2027's operating cash flow?
Israel Acquisitions Equties Warrants Exp 12 Dec 2027 (ISRLW) generated -$258K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Israel Acquisitions Equties Warrants Exp 12 Dec 2027's total assets?
Israel Acquisitions Equties Warrants Exp 12 Dec 2027 (ISRLW) had $10.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Israel Acquisitions Equties Warrants Exp 12 Dec 2027's current ratio?
Israel Acquisitions Equties Warrants Exp 12 Dec 2027 (ISRLW) had a current ratio of 1.24 as of fiscal year 2025, which is considered adequate.
What is Israel Acquisitions Equties Warrants Exp 12 Dec 2027's debt-to-equity ratio?
Israel Acquisitions Equties Warrants Exp 12 Dec 2027 (ISRLW) had a debt-to-equity ratio of -2.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Israel Acquisitions Equties Warrants Exp 12 Dec 2027's return on assets (ROA)?
Israel Acquisitions Equties Warrants Exp 12 Dec 2027 (ISRLW) had a return on assets of -5.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Israel Acquisitions Equties Warrants Exp 12 Dec 2027's cash runway?
Based on fiscal year 2025 data, Israel Acquisitions Equties Warrants Exp 12 Dec 2027 (ISRLW) had $7K in cash against an annual operating cash burn of $258K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Israel Acquisitions Equties Warrants Exp 12 Dec 2027's debt-to-equity ratio negative or unusual?
Israel Acquisitions Equties Warrants Exp 12 Dec 2027 (ISRLW) has negative shareholder equity of -$8.0M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Israel Acquisitions Equties Warrants Exp 12 Dec 2027's Piotroski F-Score?
Israel Acquisitions Equties Warrants Exp 12 Dec 2027 (ISRLW) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Israel Acquisitions Equties Warrants Exp 12 Dec 2027's earnings high quality?
Israel Acquisitions Equties Warrants Exp 12 Dec 2027 (ISRLW) has an earnings quality ratio of 0.51x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Israel Acquisitions Equties Warrants Exp 12 Dec 2027?
Israel Acquisitions Equties Warrants Exp 12 Dec 2027 (ISRLW) scores 3 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.